| Literature DB >> 21899733 |
Courtenay Dunn-Lewis1, William J Kraemer, Brian R Kupchak, Neil A Kelly, Brent A Creighton, Hui-Ying Luk, Kevin D Ballard, Brett A Comstock, Tunde K Szivak, David R Hooper, Craig R Denegar, Jeff S Volek.
Abstract
BACKGROUND: While exercise acts to combat inflammation and aging, the ability to exercise may itself be compromised by inflammation and inflammation's impact on muscle recovery and joint inflammation. A number of nutritional supplements have been shown to reduce inflammation and improve recovery. The purpose of the current investigation was to examine the effect of a multi-nutrient supplement containing branched chain amino acids, taurine, anti-inflammatory plant extracts, and B vitamins on inflammatory status, endothelial function, physical function, and mood in middle-aged individuals.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21899733 PMCID: PMC3180350 DOI: 10.1186/1475-2891-10-90
Source DB: PubMed Journal: Nutr J ISSN: 1475-2891 Impact factor: 3.271
Ingredients of Biocharge® supplement
| Supplement Facts | ||
|---|---|---|
| Vitamin B12 | 0.25 mg | 4200% |
| Vitamin B6 | 6 mg | 300% |
| Folic acid (Vitamin B9) | 0.40 mg | 100% |
| Pantothenic Acid (Vitamin B5) | 20 mg | 200% |
| Taurine | 500 mg | * |
| 1-Leucine | 2000 mg | * |
| Isoleucine | 500 mg | * |
| Valine | 500 mg | * |
| Cat's Claw (uncaria tomentosa) | 100 mg | * |
| Quercitin | 100 mg | * |
| Green tea | 50 mg | * |
| Biovin grape extract (full spectrum whole grape extract). | 25 mg | * |
| *Daily Value (DV) not established | ||
Other ingredients: natural and artificial flavor, citric acid, sucralose. The supplement is comprised of food-grade ingredients. It contains ingredients that the FDA has either approved as food additives or considers "generally recognized as safe".
Figure 1Experimental Design. Participants were randomly assigned to begin with either the multi-nutrient supplement or placebo supplement to begin in a balanced fashion. After a wash-out period, subjects completed the opposite supplement. Testing occurred immediately prior to and immediately following the 28-day supplementation periods.
Figure 2Interleukin-6 (IL-6). There was a significant decrease in interleukin-6 for both men and women from pre-supplementation, * = P ≤ 0.05 from corresponding pre-BioCharge and placebo conditions. Grey: men; white: women.
Physiological markers of inflammation in response to supplementation
| Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|
| Creatine Kinase (IU·L-1) | 92 ± 25 | 80 ± 32 | 96 ± 34 | 67 ± 23* | 68 ± 42 | 69 ± 50 | 66 ± 32 | 62 ± 33 |
| Cortisol (nmol·L-1) | 557 ± 169 | 613 ± 128 | 524 ± 180 | 515 ± 187 | 560 ± 149 | 513 ± 129 | 518 ± 165 | 541 ± 148 |
| C-Reactive Protein (mg·dL-1) | 0.22 ± 0.25 | 0.19 ± 0.25 | 0.17 ± 0.24 | 0.19 ± 0.22 | 0.10 ± 0.10 | 0.11 ± 0.09 | 0.1 ± 0.1 | 0.12 ± 0.11 |
| Brachial Artery Reactivity (mm) | 4.6 ± 0.7 | 4.8 ± 0.7 | 4.7 ± 0.8 | 4.9 ± 0.8 | 3.7 ± 0.6 | 4.1 ± 0.6 | 3.8 ± 0.5 | 4.1 ± 0.5 |
No significant differences were seen for placebo (either pre/post placebo or as compared to pre-supplementation). Pre Suppl = Pre-Supplementation testing; Post Suppl = Post-Supplementation testing. *p ≤ 0.05 as compared to supplementation pre-testing.
Figure 3Alpha-1 Antichymotrypsin. There was a significant decrease in alpha-1 antichymotrypsin for men from pre-supplementation, * = P ≤ 0.05 from corresponding pre-BioCharge and placebo conditions. Grey: men; white: women.
Perceptual markers in response to supplementation (area under the curve)
| Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|
| Energy | - | 1.8 ± 0.7^ | - | 3.7 ± 0.8* | - | 1.2 ± 0.7^ | - | 2.8 ± 0.8* |
| Anxiety | 43 ± 6.3 | 42 ± 5.6 | 43 ± 7.2 | 43 ± 7.4 | 50 ± 6.5 | 49 ± 6.5 | 53 ± 8.9 | 45 ± 8.3* |
| Fatigue | 44.9 ± 4.6 | 43.7 ± 4.5 | 46.9 ± 5 | 35.8 ± 6.7* | 42.4 ± 9 | 43.3 ± 5.3 | 43 ± 9.3 | 43.2 ± 9.5 |
| Joint Pain | 1.1 ± 0.3 | 1.1 ± 0.3 | 1.2 ± 0.2 | 0.5 ± 0.3* | 0.7 ± 0.2 | 0.8 ± 0.1 | 0.7 ± 0.2 | 0.7 ± 0.2 |
| Pain Intensity | 0.8 ± 0.06 | 1.1 ± 0.08 | 1.1 ± 0.09 | 0.6 ± 0.06* | 0.8 ± 0.07 | 0.7 ± 0.08 | 0.6 ± 0.06 | 0.6 ± 0.08 |
Please note (as applicable) that no differences were seen in placebo (either pre/post placebo or as compared to pre-supplementation). Pre Suppl = Pre-Supplementation testing; Post Suppl = Post-Supplementation testing. *p ≤ 0.05 as compared to supplementation pre-testing; ^p < 0.05 as compared to placebo.
Performance responses to supplementation
| Men | Women | |||||||
|---|---|---|---|---|---|---|---|---|
| Postural Sway (cm) | 0.53 ± 0.10 | 0.48 ± 0.13 | 0.51 ± 0.16 | 0.56 ± 0.22 | 0.52 ± 0.14 | 0.52 ± 0.12 | 0.52 ± 0.13 | 0.45 ± 0.12* |
| Vertical Jump (W) | 2697 ± 212 | 2761 ± 322 | 2642 ± 244 | 3134 ± 282* | 2006 ± 244 | 2046 ± 282 | 2077 ± 229 | 2039 ± 409 |
| Grip Strength (kg) | 41.5 ± 6.1 | 41.8 ± 6.2 | 42.1 ± 5.9 | 48.5 ± 4.9* | 31.6 ± 4.6 | 33.3 ± 4.5 | 33 ± 5.1 | 33.3 ± 5.5 |
No significant differences were seen in placebo (either pre/post placebo or as compared to pre-supplementation). Pre Suppl = Pre-Supplementation testing; Post Suppl = Post-Supplementation testing. *p ≤ 0.05 as compared to supplementation pre-testing